Type 1 Diabetes Research Study
Researchers at Indiana University School of Medicine are conducting a study on the safety and tolerability of CNP-103 for individuals ages 12–35 with recent-onset type 1 diabetes.
Fast Facts
Diagnosed with type 1 diabetes within the last 6 months
Ages 12-35
Compensation
Provided
Conducted in
Indianapolis, Indiana
Study Background
Evaluating the safety and tolerability of CNP-103 in newly diagnosed type 1 diabetics.
This research study aims to learn how safe and tolerable CNP-103 is for people recently diagnosed with type 1 diabetes. CNP-103 is a biodegradable nanoparticle containing specialized cell proteins and an investigational drug that is not yet approved by the FDA for the treatment of type 1 diabetes. By participating, individuals help advance scientific understanding of potential new therapies for type 1 diabetes.
Participants who join this study will receive careful monitoring by a team of experienced medical professionals. The study includes screening, three infusions of the investigational drug, and several follow-up visits to assess safety, health, and changes in medical status. Safety measures include in-person check-ins, frequent communication, and a 24-hour contact line to respond to any concerns quickly.
Study Background
Evaluating the safety and tolerability of CNP-103 in newly diagnosed type 1 diabetics.
This research study aims to learn how safe and tolerable CNP-103 is for people recently diagnosed with type 1 diabetes. CNP-103 is a biodegradable nanoparticle containing specialized cell proteins and an investigational drug that is not yet approved by the FDA for the treatment of type 1 diabetes. By participating, individuals help advance scientific understanding of potential new therapies for type 1 diabetes.
Participants who join this study will receive careful monitoring by a team of experienced medical professionals. The study includes screening, three infusions of the investigational drug, and several follow-up visits to assess safety, health, and changes in medical status. Safety measures include in-person check-ins, frequent communication, and a 24-hour contact line to respond to any concerns quickly.
Additional Information
This study is being conducted to evaluate the safety and tolerability of CNP-103 in individuals recently diagnosed with type 1 diabetes and to help researchers understand whether it could be a safe treatment option in the future.
You/your child may be eligible for this study if you/your child meets the following criteria.
Inclusion Criteria:
- Diagnosed with type 1 diabetes within the last 6 months
- Ages 12-35
- Weigh at least 77 pounds (>35 kg)
Participants will attend approximately 10 in-person visits over a 1 year period, including:
-
Screening visit: Health history, medications, and medical tests.
-
Three dosing visits: Receive the investigational drug and be monitored for safety.
-
Follow-up visits: Health checks, medication discussions, and medical tests to track changes in health.
-
End-of-study visit: Confirm safety and discuss possible long-term follow-up.
Yes, participants are compensated for each visit, with payments ranging from $238 to $638 depending on the visit.
Perks & Transportation Options:
Transportation support is available for study visits within a 145-mile radius of Indianapolis, Indiana.
Minor participants must have a parent, guardian, or legally authorized representative present.
Participants will have access to a dedicated study team and a 24-hour phone line for any questions or concerns.
All visits include comprehensive medical monitoring and check-ins by experienced doctors and study staff.
There is no cost for you to participate in our research study.